Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment

Filing Services Canada July 16, 2018

Theralase Releases AGM Videos

Filing Services Canada June 29, 2018

Theralase Researchers Receive Government Grant

Filing Services Canada June 28, 2018

Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin(R) Based Photo Dynamic Therapy, in Immune Privileged Sites

Filing Services Canada June 22, 2018

Theralase Cancer Therapy: In Search of Medicine’s Holy Grail

Jeff Nielson June 21, 2018

Theralase(R) Demonstrates Significant Advantage in Treatment of Brain Tumours

Filing Services Canada June 11, 2018

Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug

Filing Services Canada June 6, 2018

Theralase Release 1Q2018 Financial Statements

Filing Services Canada May 30, 2018

Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 17, 2018

Theralase Announces Completion of Non-Brokered Private Placement of Units for Aggregate Gross Proceeds of Approximately $1.02 million

Filing Services Canada May 14, 2018

Theralase Announces Proposed Non-Brokered Private Placement of up to $1 Million

Filing Services Canada May 8, 2018

Theralase Increases Revenue 22% for 2017 Financial Statements

Filing Services Canada April 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study

Filing Services Canada April 16, 2018

Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

Filing Services Canada March 27, 2018

Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells

Filing Services Canada March 15, 2018

Rutherrin(R) Technology Granted Allowance for Canadian Patent

Filing Services Canada March 7, 2018

Theralase Advances Anti-Cancer Technology in Destruction of Human Lung Cancer

Filing Services Canada March 5, 2018

Theralase Announces Settlement Agreement with Ontario Securities Commission

Filing Services Canada February 26, 2018

Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

Filing Services Canada February 9, 2018